ストックスクリーナーアプリを入手
2.33
0.43%
0.01
アフターアワーズ：
2.32
-0.01
-0.43%
前日終値:
$2.32
開ける：
$2.25
24時間の取引高:
352.11K
Relative Volume:
0.87
時価総額：
$116.66M
収益：
$17.63M
当期純損益:
$-57.71M
株価収益率:
-1.5743
EPS:
-1.48
ネットキャッシュフロー:
$-60.45M
1週間 パフォーマンス:
-11.41%
1か月 パフォーマンス:
-20.48%
6か月 パフォーマンス:
-42.75%
1年 パフォーマンス:
-53.68%
1日の値動き範囲:
$2.15
$2.4177
1週間の範囲:
$2.15
$2.615
52週間の値動き範囲:
$2.15
$5.65
Scpharmaceuticals Inc Stock (SCPH) Company Profile
名前
Scpharmaceuticals Inc
セクター
電話
617-517-0730
住所
25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA
SCPH を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SCPH
Scpharmaceuticals Inc
|
2.33 | 116.66M | 17.63M | -57.71M | -60.45M | -1.48 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.56 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.78 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
550.00 | 33.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.95 | 30.15B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
220.54 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Scpharmaceuticals Inc Stock (SCPH) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-09-07 | 開始されました | Craig Hallum | Buy |
| 2022-12-01 | 開始されました | Cowen | Outperform |
| 2022-10-21 | 再開されました | Jefferies | Buy |
| 2022-10-11 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-02 | 開始されました | Maxim Group | Buy |
| 2021-09-09 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-10-15 | 開始されました | H.C. Wainwright | Buy |
| 2019-01-30 | ダウングレード | Leerink Partners | Outperform → Mkt Perform |
すべてを表示
Scpharmaceuticals Inc (SCPH) 最新ニュース
U.S. FDA approves ScPharmaceuticals' heart failure therapy - MarketScreener
Market Cool On scPharmaceuticals Inc.'s (NASDAQ:SCPH) Revenues Pushing Shares 30% Lower - simplywall.st
Charles Schwab Investment Management Inc. Acquires 26,964 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
Bank of New York Mellon Corp Raises Stock Position in scPharmaceuticals Inc. (NASDAQ:SCPH) - Defense World
scPharmaceuticals stock hits 52-week low at $2.73 By Investing.com - Investing.com South Africa
scPharmaceuticals stock hits 52-week low at $2.73 - Investing.com India
Maxim Group Cuts scPharmaceuticals (NASDAQ:SCPH) Price Target to $12.00 - Defense World
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2024 Earnings Call Transcript - Insider Monkey
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Report Preview: Wh - GuruFocus
ScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025 - MSN
Optimistic Buy Rating for scPharmaceuticals Amid Strong Q4 Results and Promising Developments - TipRanks
Analyst Expectations For scPharmaceuticals's Future - Benzinga
Maxim Adjusts Price Target on scPharmaceuticals to $12 From $20, Keeps Buy Rating - Marketscreener.com
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: Revenue Surge and Strategic ... - Yahoo Finance
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - The Manila Times
scPharmaceuticals Inc (SCPH) Q4 2024 Earnings Call Highlights: R - GuruFocus
scPharmaceuticals Reports Strong Revenue Growth in 2024 - TipRanks
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast By Investing.com - Investing.com Australia
Earnings call transcript: SC Pharmaceuticals Q4 2024 beats EPS forecast - Investing.com
scPharmaceuticals Inc. SEC 10-K Report - TradingView
ScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
scPharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
scPharmaceuticals Inc (SCPH) Q4 Earnings: EPS Misses, Revenue Be - GuruFocus
SCPHARMACEUTICALS Earnings Results: $SCPH Reports Quarterly Earnings - Nasdaq
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Earnings Scheduled For March 19, 2025 - Benzinga
SCPHARMACEUTICALS Earnings Preview: Recent $SCPH Insider Trading, Hedge Fund Activity, and More - Nasdaq
ScPharma Eyes New Frontiers For Furoscix - RTTNews
scPharmaceuticals - The Pharma Letter
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025 - The Manila Times
scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, ... - Post Register
scPharmaceuticals Readies Major Financial Update: Q4 and Full Year Results Coming March 19 - Stock Titan
Breakthroughs in Hyperkalemia DrugsMarket Opportunities - openPR
Scpharmaceuticals at Leerink’s Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Acquired by Rhumbline Advisers - Defense World
scPharmaceuticals (SCPH) to Release Earnings on Wednesday - Armenian Reporter
FDA approves scPharmaceuticals’ Furoscix sNDA for oedema in CKD - Yahoo
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on scPharmaceuticals stock, $18 target - Investing.com India
Strategic Market Expansion and Strong Sales Foundation Drive Buy Rating for scPharmaceuticals - TipRanks
HC Wainwright Cuts Earnings Estimates for scPharmaceuticals - Defense World
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the FUROSCIX® Indication to Include the Treatment of Edema in Patients with Chronic Kidney Disease - The Manila Times
ScPharmaceuticals Says US FDA Approves Application to Expand Use of Furoscix -March 06, 2025 at 05:42 pm EST - Marketscreener.com
FDA Approves Expansion for Furosemide Injection to Treat Edema In Patients With CKD - Pharmacy Times
scPharmaceuticals Announces FDA Approval of Supplemental New Drug Application Expanding the ... - The Bakersfield Californian
FUROSCIX Scores Crucial FDA WinNew CKD Treatment Could Transform Patient Care - StockTitan
SCPH stock touches 52-week low at $3.07 amid market challenges By Investing.com - Investing.com South Africa
SCPH stock touches 52-week low at $3.07 amid market challenges - Investing.com India
FY2029 Earnings Forecast for SCPH Issued By HC Wainwright - Defense World
ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy? - Nasdaq
scPharmaceuticals (SCPH) Projected to Post Quarterly Earnings on Wednesday - Defense World
Scpharmaceuticals Inc (SCPH) 財務データ
収益
当期純利益
現金流量
EPS
0.48%
大文字化:
|
ボリューム (24 時間):